Project

Impact on angiogenesis and ER stress and its effect on chemoresistance through P1GF inhibition in a mice model of hepatocellular carcinoma.

Code
01D20012
Duration
01 October 2012 → 30 September 2016
Funding
Regional and community funding: Special Research Fund
Research disciplines
  • Medical and health sciences
    • Cardiac and vascular medicine
    • Gastro-enterology and hepatology
    • Laboratory medicine
    • Morphological sciences
    • Oncology
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other basic sciences
    • Cardiac and vascular medicine
    • Gastro-enterology and hepatology
    • Laboratory medicine
    • Morphological sciences
    • Oncology
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other clinical sciences
    • Other health sciences
    • Nursing
    • Other paramedical sciences
    • Cardiac and vascular medicine
    • Gastro-enterology and hepatology
    • Laboratory medicine
    • Morphological sciences
    • Oncology
    • Palliative care and end-of-life care
    • Regenerative medicine
    • Other translational sciences
    • Other medical and health sciences
Keywords
ER stress angiogenesis hepatocellular carcinoma chemoresistance anti-placental growth factor farnesylthiosalicylic acid
 
Project description

Hepatocellular carcinoma is third cause of cancer-related mortality. Cytostatics provide no improved survival. Chemoresistance modification is needed. Hypoxia and endoplasmic reticulum stress can cause chemoresistance. The efficacy of anti-P1GF suggests that this may be a future antineoplastic. Farnesylthiosalicylic acid is RAS competitor. HCC mouse model is used to evaluate anti-P1GF and farnesylthiosalicylic acid on hypoxia, ER stress and chemoresistance.